Ferraz Daniel, Bressanim Gláucio, Takahashi Beatriz, Pelayes David, Takahashi Walter
Department of Ophthalmology, University of São Paulo Medical School, São Paulo, Brazil.
Eur J Ophthalmol. 2010 Jul-Aug;20(4):740-4. doi: 10.1177/112067211002000415.
To evaluate the change in vision after 3 monthly consecutive intravitreal injections of 1.25 mg of bevacizumab for neovascular age-related macular degeneration (AMD).
A retrospective analysis of 35 eyes was performed. Visual acuity (VA) at initial visit and at each follow-up visit was compared. The injection of bevacizumab was performed at 30-day intervals and patients were observed for 5 months after the last injection.
Of the 35 eyes, 9 had received previous treatment with photodynamic therapy with or without 4 mg of intravitreal triamcinolone. VA was measured in Snellen table and transformed into logMAR for statistical purposes. Mean age was 76.66 years (range, 49-90 years). There were 24 (69%) women and 11 (31%) men. Mean VA at the initial visit was 0.92 +/- 0.50. At month 1, mean VA was 0.84 +/- 0.51 and at month 2 was 0.74 +/- 0.51. At month 3, mean VA remained 0.74 +/- 0.49. Six and 8 months after the initial visit, VA was 0.79 +/- 0.49 and 0.77 +/- 0.50, respectively. The improvement in VA was statistically significant at month 2 and at the end of the follow-up (8 months) compared with the baseline VA.
Three consecutive monthly injections of intravitreal bevacizumab to treat neovascular AMD is effective in improving VA in the short-term. Longer prospective studies should be performed to confirm VA stability after the third injection.
评估连续3个月每月玻璃体腔内注射1.25mg贝伐单抗治疗新生血管性年龄相关性黄斑变性（AMD）后视力的变化。
对35只眼进行回顾性分析。比较初诊时及每次随访时的视力（VA）。每30天注射一次贝伐单抗，并在最后一次注射后观察患者5个月。
35只眼中，9只眼曾接受过光动力疗法治疗，其中部分联合或未联合4mg玻璃体腔内曲安奈德治疗。采用Snellen视力表测量视力，并将其转换为logMAR视力用于统计分析。平均年龄为76.66岁（范围49 - 90岁）。女性24例（69%），男性11例（31%）。初诊时平均视力为0.92±0.50。第1个月时，平均视力为0.84±0.51，第2个月时为0.74±0.51。第3个月时，平均视力仍为0.74±0.49。初诊后6个月和8个月时，视力分别为0.79±0.49和0.77±0.50。与基线视力相比，第2个月及随访结束时（8个月）视力改善具有统计学意义。
连续3个月每月玻璃体腔内注射贝伐单抗治疗新生血管性AMD在短期内可有效改善视力。需要进行更长时间的前瞻性研究以证实第三次注射后视力的稳定性。
